No Data
Returns on Capital Paint A Bright Future For APT Medical (SHSE:688617)
China Approves APT Medical Unit's Atrial Fibrillation Treatment Device
Research Reports Mining丨Guosheng Securities: APT Medical Inc.'s PFA products have good safety and effectiveness, maintaining a "Buy" rating.
Guosheng Securities' Research Reports pointed out that APT Medical Inc. (688617.SH) PFA product integrates three major functional characteristics, possessing good safety and efficacy. The company's PFA innovative product is the first in the Global to combine "pressure sensing / contact indication" + "magnetic定位三维标测" + "pulse ablation" into one ablation system, featuring unique technical advantages. The approval of the company's PFA products has enriched the product layout in the electrophysiology field, and there is Bullish outlook on Mindray's entry enabling the company's continuous research and development and sales at home and abroad. The proportion of China's atrial fibrillation pulsed electric field ablation Medical Devices in the cardiac electrophysiology devices will also continue to increase.
APT Medical Gets Registration Certificate for Two Cardiac Devices
APT Medical Inc. (688617.SH): Obtained the medical instruments registration certificate.
On December 16, Gelonghui reported that APT Medical Inc. (688617.SH) announced that the company has obtained a medical instruments registration certificate, and its wholly-owned subsidiary Shanghai Hongtong Industrial Co., Ltd. has obtained a medical instruments registration certificate and a medical instruments change registration document. Product names: disposable cardiac pulsed electric field ablation catheter, cardiac pulsed electric field ablation device, three-dimensional cardiac electrophysiological mapping system. The acquisition of the above medical instruments registration certificates is beneficial for enriching the company's product variety, expanding the company's product layout in the electrophysiology field, continuously meeting diverse clinical needs, and further enhancing the company's core competitive ability.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
If EPS Growth Is Important To You, APT Medical (SHSE:688617) Presents An Opportunity
No Data
